Bevacizumab biosimilar - mAbxience

Drug Profile

Bevacizumab biosimilar - mAbxience

Alternative Names: Bevax; BEVZ92; MB02

Latest Information Update: 29 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator mAbxience
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase III Non-small cell lung cancer
  • No development reported Cancer

Most Recent Events

  • 23 May 2018 Amneal enters into a commercialisation agreement with mAbxience for bevacizumab biosimilar in the US
  • 19 Feb 2018 Bevacizumab biosimilar is still in phase I trials for Colorectal-cancer(First-line therapy, Metastatic disease) in India, Ukraine, Brazil, Spain, Argentina (IV, Infusion) (NCT02069704)
  • 06 Feb 2018 Phase-III clinical trials in Non-small cell lung cancer (Metastatic disease, Late-stage disease, Newly diagnosed, Recurrent) in Hungary, Georgia (IV) (NCT03296163) (EudraCT2017-001769-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top